Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
IBUPROFEN
ANGITA PHARMA INC.
M01AE01
IBUPROFEN
200MG
TABLET
IBUPROFEN 200MG
ORAL
100
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883004; AHFS:
APPROVED
2020-04-23
_Page 1 / 40_ PRODUCT MONOGRAPH IBUPROFEN Ibuprofen Tablets USP 200mg and 400 mg Non-Steroidal Anti-inflammatory Drug Analgesic, Antipyretic Agent Angita Pharma Inc. 1310 Nobel Street, Boucherville, Québec Canada, J4B 5H3 Date of Preparation: February 26, 2020 Control # 236574 _Page 2 / 40_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................... 3 INDICATIONS AND CLINCAL USE ........................................................................................... 3 CONTRAINDICATIONS ............................................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS ................................................................................................................ 9 DRUG INTERACTIONS .............................................................................................................. 12 DOSAGE AND ADMINISTRATION .......................................................................................... 15 OVERDOSAGE .................................................................................................................................. 16 ACTION AND CLINICAL PHARMACOLOGY ........................................................................ 16 STORAGE AND STABILITY ...................................................................................................... 17 SPECIAL HANDLING INSTRUCTIONS .................................................................................. 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................................... 18 PART II: SCIENTIFIC INFORMATION ................................................................................ 19 PHARMACEUTICAL INFORMATION .................. Διαβάστε το πλήρες έγγραφο